Cancer Therapy
Ovarian function suppression appears comparable to chemotherapy in young women
Published in Cancer Weekly, January 31st, 2006
According to a researcher in Switzerland, "A small minority of breast cancer patients consists of young women (<40 years: <6%). Thus, they may not be properly represented in clinical trials. They present with unfavorable tumor characteristics, but young age is an independent negative prognosticator: age is a surrogate for biological mechanisms determining an aggressive cancer phenotype."
S. Aebi cited, "In premenopausal patients with estrogen receptor-positive (ER+) tumors, adjuvant ovarian function suppression (OSF) was as effective as...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-01-31)
More Articles from Cancer Weekly
- Cancer Drugs
New class of platinum-based antitumorals may improve outcomes in cancer patients - Cancer Research
Study shows tumor cells bordering normal tissue receive signals to wander - Cancer Risk Factors
Environmental factors accelerated evolution of extensive intestinal metaplasia - Glioblastoma Multiforme
Chromosome 7 conferred radiation resistance in human glioblastoma multiforme - Lung Cancer
Cancer-testis genes associated with poor outcome in non-small cell lung cancer - Acute Myeloid Leukemia
FAB and WHO classification of acute myeloid leukemia discussed - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
